DOD Biotech PCL (BKK:DOD-R) YoY EPS Growth: -90.48% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:DOD-R DOD Biotech PCL BKK:DOD-R
67 GF Score
Price ฿0.97
GF Value ฿1.52
! 6 Warning Signs
View Full Analysis

What is DOD Biotech PCL YoY EPS Growth?

DOD Biotech PCL BKK:DOD-R -5.84% 67 YoY EPS Growth is -90.48% as of Jun. 2026. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. DOD Biotech PCL's YoY EPS Growth for the quarter that ended in Jun. 2026 was -90.48%.

DOD Biotech PCL's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was ฿0.00.

DOD Biotech PCL YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for DOD Biotech PCL's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DOD Biotech PCL YoY EPS Growth Chart

DOD Biotech PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.60 -908.33 102.06 -1,850.00 137.14

DOD Biotech PCL Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.53 37.50 188.89 -181.67 -90.48
BKK:DOD-R
67GF Score
DOD Biotech PCL BKK:DOD-R
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DOD Biotech PCL YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

DOD Biotech PCL's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(0.13--0.35)/ | -0.35 |
=137.14 %

DOD Biotech PCL's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.002-0.021)/ | 0.021 |
=-90.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -90.48% mean?
DOD Biotech PCL (BKK:DOD-R) has a YoY EPS Growth of -90.48% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for DOD Biotech PCL and its competitors.
Is DOD Biotech PCL's YoY EPS Growth too high?
DOD Biotech PCL's current YoY EPS Growth is -90.48%. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's YoY EPS Growth compare to KHC and GIS?
DOD Biotech PCL's YoY EPS Growth of -90.48% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Consumer Packaged Goods company?
A good YoY EPS Growth depends on the Consumer Packaged Goods industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for DOD Biotech PCL and its competitors. DOD Biotech PCL's current YoY EPS Growth is -90.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current YoY EPS Growth of -90.48%. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current YoY EPS Growth is -90.48%. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current YoY EPS Growth is -90.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?

Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued. The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.

Key valuation signals for BKK:DOD-R:

  • YoY EPS Growth: -90.48%
  • GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DOD Biotech PCL Business Description

Other Exchanges DOD:Thailand
Address No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score

Get the complete analysis for BKK:DOD-R

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿0.97
Price
฿1.52
GF Value